MIRM — Mirum Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1759425 ·
Last close
$98.90
Market Cap
$6.03B
52W High
$114.99
52W Low
$84.33
ADV30
1,047,462
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 159,882,000 | 131,077,000 | -63,163,000 | -790,155,000 | 890,916,000 | 324,907,000 | 648,422,000 |
| Dec 2025 | 148,932,000 | 120,668,000 | -4,567,000 | -5,730,000 | 842,813,000 | 296,683,000 | 528,123,000 |
| Sep 2025 | 133,010,000 | 107,473,000 | 2,603,000 | 2,905,000 | 785,115,000 | 282,021,000 | 493,069,000 |
| Jun 2025 | 127,785,000 | 104,364,000 | -4,989,000 | -5,861,000 | 725,825,000 | 228,122,000 | 470,667,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-170,975,000
Investing CF
$-19,389,000
Financing CF
$303,862,000
CapEx
$-11,577,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.61
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,457,699,000
Inventory
$25,518,000
Receivables
$133,113,000
ST Investments
$61,352,000
EBIT TTM
$-783,050,000
Pretax Income TTM
$-797,459,000
Interest Exp TTM
$14,409,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$569,609,024
EBITDA
$-50,050,000
Free Cash Flow
$166,895,872
Enterprise Value
$5,951,488,512
Total Cash
$386,259,008
Total Debt
$323,779,008
Shares Out
60,981,227
Trailing EPS
$-13.60
Book Value
$3.98
ROE
-335.8%
ROA
-5.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 521,312,000 | -22,136,000 | -23,363,000 | 842,813,000 | 528,123,000 | — | 55,827,000 |
| Dec 2024 | 336,888,000 | -87,606,000 | -87,942,000 | 670,754,000 | 445,114,000 | — | 10,325,000 |
| Dec 2023 | 186,374,000 | -109,154,000 | -163,415,000 | 646,621,000 | 397,951,000 | — | -70,944,000 |
| Dec 2022 | 77,062,000 | -131,220,000 | -135,665,000 | 352,906,000 | 210,869,000 | — | -120,136,000 |
TTM Snapshot
Revenues TTM
$138,102,000
NetIncome TTM
$-37,823,000
OpCashFlow TTM
$0
Assets (Latest)
$670,754,000
Forward EPS
$-0.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TGTX | TG THERAPEUTICS, INC. | $6.08B | $39.73 | — |
| TERN | Terns Pharmaceuticals, Inc. | $6.12B | $52.95 | — |
| CNTA | Centessa Pharmaceuticals plc | $6.16B | $39.78 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.16B | $89.82 | — |
| ALKS | Alkermes plc. | $6.23B | $37.35 | — |
News headlines (Yahoo Finance, 1h cache)
Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)
2026-05-25 16:10 · Yahoo
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
2026-05-21 12:05 · Yahoo
Mirum Pharma: A Rare Disease Growth Story to Watch
2026-05-20 16:35 · Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-14 20:01 · Yahoo
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
2026-05-13 03:56 · Yahoo
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
2026-05-12 20:01 · Yahoo
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-12 12:00 · Yahoo
Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss - Has The Bull Case Changed?
2026-05-07 22:17 · Yahoo
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
2026-05-07 16:04 · Yahoo
Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up
2026-05-07 14:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.